Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.65 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.65 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28681622 | 0.92 | CYP2C9 (0.55) | CYP2C9PTGER2PTGDRPTGDR2 | |
| SCHEMBL28668268 | 0.89 | PTGDR2 (0.56) | CYP2C9PTGDR2 | |
| SCHEMBL29246417 | 0.89 | PTGDR2 (0.54) | CYP2C9PTGDR2 | |
| SCHEMBL28683406 | 0.88 | CYP2C9 (0.65) | CYP2C9PTGER2PTGDRPTGDR2 | |
| SCHEMBL28669528 | 0.87 | — | — | |
| SCHEMBL28930615 | 0.87 | PTGDR2 (0.54) | CYP2C9PTGDR2 | |
| SCHEMBL28689653 | 0.85 | PTGDR2 (0.52) | CYP2C9PTGDR2 | |
| SCHEMBL28688188 | 0.84 | CYP2C9 (0.51) | CYP2C9PTGDR2 | |
| SCHEMBL28661805 | 0.83 | HDAC6 (0.73) | — | |
| SCHEMBL28688118 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113845522-A | Aminopeptidase N inhibitor and preparation method and application thereof | 山东省药学科学院 | 2021-12-28 | — | — | CN | claimed |
| CN-113845522-B | Aminopeptidase N inhibitor and preparation method and application thereof | 山东省药学科学院 | 2024-05-14 | — | — | CN | disclosed |
| CN-113845522-A | Aminopeptidase N inhibitor and preparation method and application thereof | 山东省药学科学院 | 2021-12-28 | — | — | CN | disclosed |